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Abstract
Background: Pancreatic cancer is among the top 5 most common cancers worldwide, but is particularly
devastating due to its insidious nature. Complete surgical resection remains the only potential curative treatment,
although only 20 % of patients present with a resectable tumor. Patients may alternatively present with borderline
resectable pancreatic cancer or locally advanced pancreatic cancer and can be offered treatment with neoadjuvant
intent. The effectiveness of these treatments is unclear and there is a paucity of data to suggest one optimal
treatment approach.
Case presentation: We describe a 61-year-old female who presented with a two-week history of obstructive
jaundice in the context of vague abdominal pain that had been ongoing for years prior to her visit. CT scan of the
abdomen confirmed a hypovascular mass in the uncinate process consistent with borderline resectable pancreatic
cancer. Pancreatic adenocarcinoma was confirmed with endoscopic ultrasound guided fine-needle aspiration
cytology. Following multidisciplinary discussion, it was recommended that she undergo treatment with
FOLFIRINOX. After a total of 13 cycles, follow up CT revealed that the lesion had decreased in size and she was
offered resection as a potentially curative treatment. She underwent pancreaticoduodenectomy. Final pathology
report revealed no evidence of residual adenocarcinoma (ypT0 ypN0 (0/23)). The patient remains disease-free
15 months following surgery.
Conclusion: To date, there have been very few reports of a complete pathological response following neoadjuvant
therapy in borderline resectable or locally advanced pancreatic cancer. This report describes a unique case of a
complete pathological remission in a patient with borderline resectable pancreatic cancer following FOLFIRINOX
therapy alone and adds to the growing base of evidence meriting the initiation of clinical trials to assess the
efficacy of FOLFIRINOX in these subsets of pancreatic cancer.
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Background
Pancreatic adenocarcinoma is one of the top five causes
of cancer death worldwide. It is particularly devastating
due to its insidious progression. The red flag symptoms
prompting diagnosis often appear only once the disease
has already progressed or metastasized. As a result, only
10–20 % of pancreatic cancers are resectable at the time
of presentation and the overall 5-year survival rate is less
than 5 % [1, 2].
Early intervention in non-metastatic pancreatic cancer
is crucial as metastases have been shown to occur unex-
pectedly before clinical detection is possible [3–5]. Sur-
gical resection is thought to be the only curative
treatment for pancreatic adenocarcinoma and offers a
five year survival rate of 10–15 % [1, 6, 7]. Neoadjuvant
chemotherapy is often implemented in an effort to in-
crease the incidence of R0 resections, reduce local recur-
rences, treat occult micrometastases, and to downstage a
borderline resectable tumor to the point of possible re-
section [1].
A subset of patients is considered to have borderline
resectable pancreatic cancer, which can be classified
using three main staging systems. The first staging sys-
tems were established by M.D. Anderson and the Na-
tional Comprehensive Cancer Network. A third system
was put forth by the Americas Hepatopancreatobiliary
Association/Society of Surgical Oncology/Society for
Surgery of the Alimentary Tract in 2009 and was ultim-
ately adopted by the National Comprehensive Cancer
Network. Based on the M.D. Anderson criteria, border-
line resectability can be defined as tumor abutment of ≤
180° of the circumference of the superior mesenteric ar-
tery (SMA), short-segment encasement or abutment of
the common hepatic artery (typically at the gastroduode-
nal origin), or short-segment occlusion of the superior
mesenteric vein or portal vein with suitable vessels
above and below [8]. The current National Comprehen-
sive Cancer Network system is largely similar to the
M.D. Anderson criteria except that abutment (≤180°) or
encasement (>180°) of the superior mesenteric vein/por-
tal vein without vein contour irregularity is considered
borderline resectable. Thus, non-occlusive involvement
of the superior mesenteric vein or portal vein is consid-
ered only borderline resectable by the National Compre-
hensive Cancer Network criteria, but resectable by the
M.D. Anderson criteria [8–11]. Patients with borderline
resectable pancreatic cancer typically undergo chemo-
therapy and/or chemoradiation as a neoadjuvant ap-
proach, followed by radical surgical resection.
About 30 % of patients have locally advanced pancre-
atic cancer [2, 5] which is defined by the M.D. Anderson
criteria as tumor encasement of the SMA beyond 180°,
encasement of the celiac artery or hepatic artery, or oc-
clusion of the superior mesenteric vein or portal vein, all
in the absence of metastatic disease [8]. Patients with lo-
cally advanced pancreatic cancer are generally treated
with chemotherapy or chemoradiation. In the majority
of patients, this is considered palliative treatment, al-
though a small subset of patients who see a radiological
response may eventually be considered for surgical
resection.
Pathologic complete response (pCR) is used to refer to
a neoplastic tissue specimen with no residual viable in-
vasive adenocarcinoma cells within the parenchyma [12].
For several different cancer types, pCR is associated with
lower frequencies of local recurrences, distant metasta-
ses, and overall better survival rates. The significance of
pCR in pancreatic cancer has also been demonstrated by
an association with high survival rates [12, 13]. To our
knowledge, while there have been several reports of a
pCR following neoadjuvant therapy in borderline resect-
able or locally advanced pancreatic cancer [5, 14–20],
there has been only one case report of a patient who
achieved pCR with FOLFIRINOX alone [21]. This article
describes the second report of a well documented, histo-
logically proven pCR following systemic treatment with
FOLFIRINOX.
Case presentation
A 61-year-old French Canadian female presented to hos-
pital with a two-week history of obstructive jaundice,
pruritus, tea-coloured urine, acholic stools, fatigue, an-
orexia, and unintentional weight loss. Her history also
included vague abdominal pain that had been ongoing
for years prior to her visit, although the pattern of pain
did not change with the onset of jaundice. Her past
medical history included type 2 diabetes mellitus and
hypertension. She did not have a personal history of can-
cer, but her family history included two aunts who had
pancreatic cancer in their sixth decades of life. She de-
nied any tobacco, alcohol, or recreational drug use.
Abdominal ultrasound revealed a lesion in the uncin-
ate process of the pancreas. A subsequent CT scan of
the abdomen confirmed a fairly well circumscribed
hypovascular mass in the head and uncinate process of
the pancreas, radiographically consistent with pancreatic
adenocarcinoma (Fig. 1a). The mass encircled the first
jejunal branch of the superior mesenteric artery by ap-
proximately 180°. Endoscopic retrograde cholangiopan-
creatography (ERCP) was ultimately unsuccessful due to
inability to cannulate the common bile duct. The pan-
creatic duct was patent and could be cannulated but
seemed to end abruptly.
The patient underwent an endoscopic ultrasound,
which revealed a 4.8 × 3.5 cm hypoechoic mass in the
pancreatic head/uncinate process along with numerous
cystic changes in the body, tail, and distal tail of the pan-
creas, measuring 2.4 mm, 3.9 mm, and 4.3 mm,
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respectively. Fine-needle aspiration (FNA) biopsy at the
time of endoscopic ultrasound demonstrated cytology
consistent with adenocarcinoma (Fig. 2).
At the time of diagnosis, the patient’s functionality was
consistent with Eastern Cooperative Oncology Group
(ECOG) grade 1: restricted in physically strenuous activ-
ity, but ambulatory and able to carry out light work. The
CA19-9 levels were ordered but deferred by the patient.
Her total bilirubin at the time of diagnosis was
160 μmol/L. The patient underwent placement of a per-
cutaneous transhepatic biliary drainage catheter, with
resolution of her jaundice. The patient was reviewed at a
weekly hepatobiliary and pancreatic cancer multidiscip-
linary conference. Consensus was that her tumor was
borderline resectable on the basis of partial encasement
of the superior mesenteric artery. Although there was
encasement of the first jejunal branch, the tumor was
staged based on abutment of less than ≤ 180° of the
Fig. 1 Abdominal CT scans. a The mass is separate from the celiac axis an there is loss of a fat plane between the mass and SMA (white arrow)
with less than 90° involvement of its circumference. The first arterial jejunal branch (red arrow) is also encased with tumor. There is also mild
narrowing of the medial aspect of the superior mesenteric vein where the tumor abuts around 90° of its circumference. The pancreatic duct is
dilated, measuring up to 6 mm. b Following 9 cycles of FOLFIRINOX, the follow up MRI reveals that the head of the pancreas has indistinct
margins, but has clearly diminished in size. The measured size is 2.7 × 2.3 mm (prior: 3.9 × 3.2 mm). Pancreatic ductal dilatation has subsided,
indicating response to treatment
Fig. 2 Photomicrographs showing cytomorphological findings of endoscopic ultrasound guided fine needle aspirate of pancreatic
adenocarcinoma. a Cellular aspirate depicting glandular cells arranged in complex architecture (Papanicolaou stain, magnification 200×). b and c
The cells are markedly pleomorphic with enlarged irregular nuclei, macronucleoli and moderate lacy cytoplasm (magnification 400× and 600×). d
Section of cell block show markedly atypical cells disposed in cribriform architecture. Frequent mitotic figures (black arrows) are also present
(magnification 400×)
Gostimir et al. BMC Cancer  (2016) 16:786 Page 3 of 8
SMA. Radiologically, the patient was staged as T3 N0
M0. It was recommended that the patient begin systemic
chemotherapy with four cycles of FOLFIRINOX (Irino-
tecan 180 mg/m2; Oxaliplatin 85 mg/m2; 5-Fluorouracil
400 mg/m2; Folinic acid 400 mg/m2), after which she
would be re-imaged for assessment of treatment efficacy.
The patient tolerated the four cycles without undue
toxicity, after which she underwent re-staging with CT
scans of the chest, abdomen, and pelvis. This revealed
multiple non-calcified small pulmonary nodules detected
bilaterally in the lower lobes, the largest of which mea-
sured 4 mm. These nodules were previously not present
and were thus considered suspicious for metastatic dis-
ease. As a result of the equivocal pulmonary nodules, re-
section was not indicated and the decision was made to
continue FOLFIRINOX to further assess both local re-
sponse, and the response of the potential metastatic
nodules.
The patient received a further nine cycles of FOLFIRI-
NOX. Follow up MRI revealed that the pancreatic lesion
had impressively decreased in size from 3.9 × 3.2 cm to
2.7 × 2.3 cm compared to the previous CT (Fig. 1b). Fur-
thermore, the lung lesions had remained stable since the
last CT scan, raising the possibility that they were not
metastatic. Given these results, and after discussion at
multidisciplinary cancer conference, a resection was of-
fered to the patient as a potentially curative treatment.
She continued two more cycles of therapy before under-
going a pancreaticoduodenectomy, six weeks following
discontinuation of FOLFIRINOX and 33 weeks from the
date of diagnosis. No major technical difficulties were
encountered in the procedure, although there was con-
siderable tissue edema as expected from the chemother-
apy. No vascular resection or reconstruction was
required. Her postoperative course was complicated by
pneumonia. She was discharged home on day 11. She
was readmitted 9 days later with acute kidney injury,
secondary to vomiting, poor intake and diarrhea,
requiring one round of hemodialysis (peak creatinine
847 μmol/L or 9.58 mg/dL, Dindo-Clavien grade 4a).
Histological examination of the surgical specimen re-
vealed no evidence of residual adenocarcinoma (Fig. 3),
consistent with a complete response to treatment (Col-
lege of American Pathologists grade 0) [22]. As is re-
quired in this situation, the entire specimen was
submitted for histological assessment, confirming the
complete pathological response (ypT0). Severe acute and
chronic pancreatitis and areas of fibrosis were noted, to-
gether with scattered foci of grade 1 pancreatic intrae-
pithelial neoplasia. All 23 resected lymph nodes were
negative for malignancy (ypN0).
Following surgery, adjuvant therapy was not given.
Her CT scans at 3 and 6 months postoperatively show
no evidence of recurrence, with no appreciable change
in her previously noted lung nodules. Her CA 19–9 is
normal at 20 kU/L. She remains disease-free 15 months
after surgery, and 24 months after diagnosis. Given her
strong family history of pancreatic cancer, she was re-
ferred for genetic testing. She was found to be a carrier
of a BRCA2 mutation that is not uncommon among
French Canadians (BRCA2: E3002K).
Discussion
The introduction of chemotherapy and radiotherapy as a
possible neoadjuvant option in borderline resectable and
locally advanced pancreatic cancer has yielded some
positive results for patients with tumors that would have
otherwise been unresectable. In a review of 111 studies,
Gillen et al. concluded that approximately one-third of
patients with initially unresectable locally advanced pan-
creatic cancer could become resectable following neoad-
juvant therapy consisting of radiotherapy, chemotherapy,
or a combination of the two [23]. Furthermore, success-
ful resection following neoadjuvant therapy in locally ad-
vanced pancreatic cancer offers a median survival of
20.5 months, similar to that of R0 resections in patients
Fig. 3 Photomicrographs showing the cytomorphological findings of pancreatic specimens following surgical resection. a Low power view of
section from resected pancreas showing residual acini and islets (arrow) while the previous tumor bed (arrowhead) shows fibrosis and a repair
reaction. (Hematoxylin eosin; original magnification × 40). b Higher magnification from the fibrotic area showing fibroblasts laying down collagen
and a scattering of inflammatory cells (Hematoxylin eosin; original magnification × 200)
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with initially resectable cases of pancreatic cancer [23].
Despite these positive results, a margin-positive resec-
tion conversely offers survival rates similar to that of pa-
tients with locally advanced pancreatic cancer who were
treated with palliative intent as well as those who had
metastatic disease at presentation [23]. Thus, the opti-
mal management approach in locally advanced pancre-
atic cancer remains unclear, as there is currently only
limited evidence to support neoadjuvant approaches.
In taking a neoadjuvant approach for locally advanced
pancreatic cancer, the goal of treatment is to increase
the likelihood of R0 resection, to obliterate micrometa-
static disease, and to select for patients with favorable
tumor biology by excluding those who progress on ther-
apy [8]. Commonly used regimens have included gemci-
tabine alone, combination gemcitabine-platinum, as well
as chemoradiotherapy using 5-FU or gemcitabine as che-
mosensitizers [24]. The optimal neoadjuvant approach
in borderline resectable pancreatic cancer is still under
investigation, but similarly to locally advanced pancreatic
cancer, common approaches involve chemoradiotherapy
or initial chemotherapy followed by radiotherapy [25].
The latter approach minimizes toxic side effects of
radiotherapy and selects for patients without early me-
tastasis while also offering potential tumour reduction
[26]. At our institution, patients with both borderline re-
sectable and locally advanced pancreatic cancer are
managed initially with FOLFIRINOX as a potentially
neoadjuvant approach. Patients are re-imaged after 4–6
cycles. To be considered an operative candidate, patients
with borderline resectable pancreatic cancer must dem-
onstrate stable disease or regression, while patients with
locally advanced pancreatic cancer must demonstrate re-
gression. These decisions are all made at a multidiscip-
linary cancer conference. Most of the existing trials for
neoadjuvant therapy have included chemoradiotherapy
and at this point the relative contributions of chemo-
therapy and radiotherapy are not well understood [27–
33].
FOLFIRINOX represents a new generation of effica-
cious combination chemotherapy regimens that may be
utilized to treat patients with similar cases of pancreatic
cancer. The efficacy of FOLFIRINOX was first demon-
strated in a study by Conroy et al. in patients with unre-
sectable pancreatic cancer [34]. A subsequent trial
reported a median survival of 11.1 months in patients
with metastatic pancreatic cancer who had received
FOLFIRINOX as compared to a median survival of
6.8 months in patients receiving gemcitabine [35]. How-
ever, despite these results, the uptake of FOLFIRINOX
into the arsenal of therapeutic options for pancreatic
cancer has been slow due to concerns of toxicity. This is
especially the case for locally advanced pancreatic cancer
due to the paucity of data supporting FOLFIRINOX as a
neoadjuvant option for this type of potentially resectable
pancreatic cancer.
There is much hope that FOLFIRINOX could usher in
a new era of downstaging of borderline resectable pan-
creatic cancer, allowing R0 resection. In a study of 18
patients with borderline resectable pancreatic cancer
who were given FOLFIRINOX, 12 patients underwent
pancreatectomy with negative margins [36]. However,
this report is the first to describe a patient who achieved
pCR with FOLFIRINOX alone. One example, reported
in 2013 by Hartlapp et al., described a patient with lo-
cally advanced pancreatic cancer treated initially with
nab-paclitaxel and gemcitabine which was eventually
switched to FOLFIRINOX alone, resulting in pCR [5]. In
their report, nab-paclitaxel and gemcitabine ultimately
led to an increase in the level of CA19-9, prompting
their switch to FOLFIRINOX. Pathological analysis of
the pancreatic head in their patient revealed no viable
cancer cells but the specimen did contain residual pan-
creatic intraepithelial neoplasia. Of note, Hartlapp et al.
speculated that their preceding use of nab-paclitaxel
might have played a vital role in increasing delivery of
the subsequent FOLFIRINOX into the tumor cells.
In 2015, Valeri et al. were the first to report a patient
with locally advanced pancreatic cancer who achieved
pCR following neoadjuvant treatment with FOLFIRI-
NOX alone (Table 1) [21]. Their patient had a locally ad-
vanced cancer of the pancreatic head that was treated
with 8 cycles of FOLFIRINOX until restaging by CT
scan demonstrated complete disappearance of the tumor
[21]. Of note, the preoperative histology results for their
patient described an undifferentiated carcinoma, which
is a rare malignant epithelial neoplasm with dismal sur-
vival rates [21]. In a 2013 study of 25 patients with either
unresectable or borderline resectable disease, Boone et
al. also achieved pCR in one patient, although the details
of this patient were not reported [14]. In a 2015 study by
Blazer et al. of 25 locally advanced and 18 borderline re-
sectable pancreatic cancer patients receiving modified
FOLFIRINOX regimens, radiographic complete response
was obtained in 9 patients. However, this study also in-
cluded some patients who received radiation therapy.
The outcomes were not sub-divided by treatment group,
and therefore the effects of FOLFIRINOX alone could
not be extrapolated [37].
Complete pathological response in the context of pan-
creatic cancer is a rare outcome. The probability of pCR
following various neoadjuvant therapy approaches in
pancreatic cancer has been shown to be 3.6 %, while the
partial response rate is 30.6 % [23]. In patients with bor-
derline resectable or locally advanced pancreatic cancer,
neoadjuvant therapy has been shown to lead to pCR in
13.6 % of patients [38]. However, these studies consid-
ered all forms of neoadjuvant therapy and currently,
Gostimir et al. BMC Cancer  (2016) 16:786 Page 5 of 8
most existing reports of pCR in pancreatic cancer in-
volve chemoradiation rather than chemotherapy alone
[6, 15–20, 39–49]. Other reports of complete responses
have been only radiologically confirmed [34, 50–52].
There are presently multiple definitions for locally ad-
vanced and borderline resectable pancreatic cancer
which have made it difficult to extrapolate conclusions
on the efficacy of FOLFIRINOX as most current studies
include heterogeneous patient populations [53].
Conclusion
The current work presented a rare occurrence of
complete pathological response in a patient with border-
line resectable pancreatic cancer following treatment
with FOLFIRINOX. Consistent adoption and reporting
of resectability classification in the initial staging of pan-
creatic cancers will allow for more homogenous study
populations and a better assessment of the impact of
neoadjuvant therapies in borderline resectable and lo-
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